Home/Pipeline/Risvodetinib

Risvodetinib

Parkinson's Disease

Pre-clinicalActive

Key Facts

Indication

Parkinson's Disease

Phase

Pre-clinical

Status

Active

Company

ABLi Therapeutics

About ABLi Therapeutics

ABLi Therapeutics is a private, preclinical-stage biotech founded in 2016 and based in Cambridge, USA. The company is pioneering a novel approach to treating neurodegenerative diseases by targeting c-Abl kinase, a protein implicated in the initiation and progression of Parkinson's disease. Using its proprietary RAMP™ platform, ABLi aims to develop brain-penetrant, selective kinase inhibitors that could offer disease-modifying benefits. Its lead candidate, risvodetinib, is positioned to break the cycle of neurodegeneration and neuroinflammation in Parkinson's.

View full company profile

Therapeutic Areas

Parkinson's Disease Neurodegenerative Diseases

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active